| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/12/2004 | WO2004012731A1 Pyrrolidine derivatives as tryptase inhibitors |
| 02/12/2004 | WO2004012730A1 Improved transdermal delivery system for the administration of rotigotine |
| 02/12/2004 | WO2004012729A1 Use of angelicin and of its structural analogues for the treatment of thalassemia |
| 02/12/2004 | WO2004012728A1 Combination of an aromatase inhibitor with a bisphosphonate |
| 02/12/2004 | WO2004012727A1 Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management |
| 02/12/2004 | WO2004012726A2 Methods for treatment and prevention of gastrointestinal conditions |
| 02/12/2004 | WO2004012725A1 Topical formulations containing ketoprofen stabilised with sulisobenzone |
| 02/12/2004 | WO2004012724A1 Antiinflammatory and analgesic preparation for external use having excellent penetration and diffusion properties |
| 02/12/2004 | WO2004012723A1 Tamoxifen containing not more than 0.006% e-isomer |
| 02/12/2004 | WO2004012722A2 Bicifadine formulation |
| 02/12/2004 | WO2004012721A2 Hot melt tts for administering rotigotine |
| 02/12/2004 | WO2004012719A1 Improved transdermal delivery system |
| 02/12/2004 | WO2004012718A1 New film coating |
| 02/12/2004 | WO2004012715A1 Sustained release formulations of metformin |
| 02/12/2004 | WO2004012714A1 Oral dosage forms of water insoluble drugs and methods of making the same |
| 02/12/2004 | WO2004012712A1 Methods and compositions for treating benign gynecological disorders, contraception, and hormone replacement |
| 02/12/2004 | WO2004012709A1 Cochleates without metal cations as the bridging agents |
| 02/12/2004 | WO2004012707A1 Ascorbic acid salt suspensions and use thereof as antioxidants |
| 02/12/2004 | WO2004012706A1 Pharmaceutical compositions containing keto-acids for endoperitoneal administration |
| 02/12/2004 | WO2004012705A1 A pharmaceutical formulation and its use in the treatment of inner ear diseases |
| 02/12/2004 | WO2004012704A1 Antibiotic product, use and formulation thereof |
| 02/12/2004 | WO2004012702A1 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof |
| 02/12/2004 | WO2004012700A2 Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release |
| 02/12/2004 | WO2004012699A2 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent |
| 02/12/2004 | WO2004012695A1 The use of alkylureas for treating acne |
| 02/12/2004 | WO2004012692A1 Oral care composition comprising tropolone compounds and essential oils |
| 02/12/2004 | WO2004012690A1 A multi component moisture triggered contolled release system that imparts long lasting cooling sensation on the target site and/or provides high impact fragrance or flavor burst |
| 02/12/2004 | WO2004012688A2 Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated cpg motifs |
| 02/12/2004 | WO2004012687A2 Crystalline and amorphous forms of beta-l-2'-deoxythymidine |
| 02/12/2004 | WO2004012684A2 M3muscarinic acetylcholine receptor antagonists |
| 02/12/2004 | WO2004012683A2 Novel druggable regions in set domain proteins and methods of using the same |
| 02/12/2004 | WO2004012677A2 Methods and compositions to treat conditions associated with neovascularization |
| 02/12/2004 | WO2004012674A2 Development of muscle mass in a mammal |
| 02/12/2004 | WO2004012671A2 Substituted furo [2,3-b] pyridine derivatives |
| 02/12/2004 | WO2004012664A2 Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| 02/12/2004 | WO2004012662A2 Improved treatment of cancer with glutamine |
| 02/12/2004 | WO2004012659A2 Nitrosated proton pump inhibitors, compositions and methods of use |
| 02/12/2004 | WO2004012657A2 Beta-glucan containing composites, methods for manufacturing and for using such composites |
| 02/12/2004 | WO2004012655A2 Anti-microbial compositions and methods of using same |
| 02/12/2004 | WO2004012654A2 Oligonucleotides for treating proliferative disorders |
| 02/12/2004 | WO2004012653A2 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 02/12/2004 | WO2004012652A2 Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| 02/12/2004 | WO2004012651A2 Composition for heart disease, method to prepare same and uses thereof |
| 02/12/2004 | WO2004012522A1 Compositions comprising lactoferrin |
| 02/12/2004 | WO2004012510A1 Critical fluid antimicrobial compositions and their use and generation |
| 02/12/2004 | WO2004012506A2 Antimicrobial compounds |
| 02/12/2004 | WO2003103610A3 Mappicine analogs, methods of inhibiting retroviral reverse transcriptase and methods of treating retroviruses |
| 02/12/2004 | WO2003103604A3 Gamma lactams as prostaglandin agonists and use thereof |
| 02/12/2004 | WO2003103596A3 Stabilized nanoparticle formulations of camptotheca derivatives |
| 02/12/2004 | WO2003097582A3 Synthesis of benzonitriles and benzimidates |
| 02/12/2004 | WO2003097025A3 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom |
| 02/12/2004 | WO2003096979A3 Drug therapy for celiac sprue |
| 02/12/2004 | WO2003095437A8 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 02/12/2004 | WO2003094957A3 Methods of therapy for inducing tolerance |
| 02/12/2004 | WO2003093410A3 Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells |
| 02/12/2004 | WO2003091259A8 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/12/2004 | WO2003090672A3 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/12/2004 | WO2003088909A3 Methods for modulating phototoxicity |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003086417B1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 02/12/2004 | WO2003086383A8 Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents |
| 02/12/2004 | WO2003086305A8 Biodegradable peg-based polymer formulations in ocular applications |
| 02/12/2004 | WO2003084473A3 Method of treating cancer |
| 02/12/2004 | WO2003079997A3 Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma |
| 02/12/2004 | WO2003079886A3 Serotonin and catecholamine system segment optimization techonology |
| 02/12/2004 | WO2003079885A3 Inhalable sustained therapeutic formulations |
| 02/12/2004 | WO2003077882A3 Preparation of sterile stabilized nanodispersions |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003070665A3 Desolvating solvates of atorvastatin hemi-calcium |
| 02/12/2004 | WO2003070236A3 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2003070171A9 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
| 02/12/2004 | WO2003065994A3 Schwann cell and phosphodiesterase inhibitors based therapy |
| 02/12/2004 | WO2003060142A3 Compositions and methods for controlled release |
| 02/12/2004 | WO2003059254A3 Prevention and treatment of atherosclerosis and restenosis |
| 02/12/2004 | WO2003057141A3 Methods for improving the aesthetic appearance of skin |
| 02/12/2004 | WO2003057136A3 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 02/12/2004 | WO2003053325A8 Microencapsulation of drugs by solvent exchange |
| 02/12/2004 | WO2003051346A3 Use of selective pde5 inhibitors for treating partial and global respiratory failure |
| 02/12/2004 | WO2003050502A3 Prospective identification and characterization of breast cancer stem cells |
| 02/12/2004 | WO2003050301A3 Susceptibility locus for schizophrenia |
| 02/12/2004 | WO2003049723A3 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity |
| 02/12/2004 | WO2003049702A3 Vanilloid receptor ligands and their use in treatments |
| 02/12/2004 | WO2003043416A3 Methods and reagents for the control of infestations of parasites |
| 02/12/2004 | WO2003039404A3 Methods for treating ocular neovascular diseases |
| 02/12/2004 | WO2003037916A3 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/12/2004 | WO2003035012A3 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 02/12/2004 | WO2003029209A3 Chemical compounds |
| 02/12/2004 | WO2003024976A3 Tricyclic indole derivatives as 5-ht ligands |
| 02/12/2004 | WO2003020700A3 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 02/12/2004 | WO2003013424A3 Use of r-nsaid compounds for anti-hiv treatment |
| 02/12/2004 | WO2003010159A8 Piperidine derivatives as nmda receptor antagonists |
| 02/12/2004 | WO2003008365A3 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2002101357A9 Molecular signatures of commonly fatal carcinomas |
| 02/12/2004 | WO2002100344A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 02/12/2004 | WO2002100330A3 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 02/12/2004 | WO2002094196A3 Method of treatment for cancers associated with elevated |
| 02/12/2004 | WO2002076941A3 Histone deacetylase inhibitors |
| 02/12/2004 | WO2002074346A3 Targeting chemical compounds to cells |
| 02/12/2004 | WO2002066647A3 Type 2 ctokine receptor and nucleic acids encoding same |
| 02/12/2004 | WO2002059609A3 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |